切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2019, Vol. 13 ›› Issue (01) : 65 -68. doi: 10.3877/cma.j.issn.1674-3946.2019.01.021

所属专题: 文献

论著

外周血SEPT9基因甲基化检测在结直肠癌筛查及术后随访中的意义分析
石会勇1,(), 赵春红2, 甄亚男1, 霍守俊1, 王若谷1   
  1. 1. 250031 山东临邑,山东省医学科学院附属医院胃肠外科
    2. 250031 山东临邑,山东省医学科学院附属医院中心实验室
  • 收稿日期:2018-02-23 出版日期:2019-02-26
  • 通信作者: 石会勇

Analysis of SEPT9 gene methylation in diagnosis and follow-up of colorectal cancer

Huiyong Shi1,(), Chunhong Zhao2, Yanan Zhen1, Shoujun Huo1, Ruogu Wang1   

  1. 1. Department of Gastrointestinal Surgery, Affiliated Hospital of Shandong Academy of Medical Sciences, Linyi Shandong 250031, China
    2. Department of Central Laboratory, Affiliated Hospital of Shandong Academy of Medical Sciences, Linyi Shandong 250031, China
  • Received:2018-02-23 Published:2019-02-26
  • Corresponding author: Huiyong Shi
  • About author:
    Corresponding author: Shi Huiyong, Email:
引用本文:

石会勇, 赵春红, 甄亚男, 霍守俊, 王若谷. 外周血SEPT9基因甲基化检测在结直肠癌筛查及术后随访中的意义分析[J/OL]. 中华普外科手术学杂志(电子版), 2019, 13(01): 65-68.

Huiyong Shi, Chunhong Zhao, Yanan Zhen, Shoujun Huo, Ruogu Wang. Analysis of SEPT9 gene methylation in diagnosis and follow-up of colorectal cancer[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(01): 65-68.

目的

探讨外周血SEPT9基因甲基化检测在结直肠癌筛查及随访中的应用。

方法

回顾性分析2014年10月至2015年12月接受结直肠癌筛查人群共计783例,其中确诊结直肠癌患者72例,非结直肠癌患者711例。对所有纳入患者进行外周血SEPT9甲基化检测和病理检查。以病理诊断为金标准,采用ROC曲线分析SEPT9阳性对结直肠癌的诊断价值,术后随访1年,观察外周血SEPT9基因甲基化和患者生存情况的关系。应用SPSS 23.0软件进行统计学分析,性别、年龄段、病变位置、TNM分期等资料以[例(%)]表示,比较采用卡方检验,以P<0.05为差异有统计学意义。

结果

结直肠癌患者SEPT9基因甲基化(70.8%)显著高于非结直肠癌患者(13.5%);SEPT9基因甲基化在TNM分期Ⅰ期、Ⅱ期、Ⅲ期及Ⅳ期结直肠癌患者的阳性率依次为:47.4%、 69.2%、 88.9%、 88.9%。ROC曲线分析显示,SEPT9的AUC=0.787,高于CA125和CA199(P<0.05),其诊断结直肠癌的灵敏度为86.5%,特异度为70.8%。术后随访1年发现,88.2%的SEPT9基因甲基化阳性患者在结直肠癌根治术后转为阴性,与SEPT9甲基化转阴性的患者相比较,SEPT9甲基化未转为阴性的患者预后较差。

结论

SEPT9基因甲基化检测可能作为评估结直肠癌风险和预后的一项重要检测指标。

Objective

To study the analysis of SEPT9 gene methylation in diagnosis and follow-up of colorectal cancer.

Methods

The clinical data of 783 cases of colorectal cancer screening in our hospital from October 2014 to December 2015 were analyzed. There were 72 patients diagnosed with colorectal cancer, 711 cases were excluded colorectal cancer. In there, all patients were performed by peripheral blood SEPT9 methylation detection and pathological examination. Pathological diagnosis was used as gold standard, with the ROC curve, the diagnostic value of SEPT9 positive for colorectal cancer was evaluated. After 1 years of follow-up, the SEPT9 gene methylation and the survival of the patients were observed. Statistical analysis were performed by using SPSS 23.0 software, the classification data such as sex, age, location of lesion, TNM stage and et al were presented as n(%), and examined by using Chi square test. A P<0.05 was considered as significant difference.

Results

The level of SEPT9 gene methylation of colorectal cancer patients was significant higher than non-colorectal cancer patients. The positive rate of SEPT9 gene methylation of colorectal cancer patients in stage Ⅰ, stage Ⅱ, stage Ⅲ and Ⅳ was 47.4%, 69.2%, 88.89%, 88.9% respectivly. ROC curve analysis showed that the SEPT9 was higher than that of CA125 and CA199 curve (P<0.05), the sensitivity and specificity of the diagnosis of colorectal cancer was 86.5% and 70.8%. After 1 year of follow-up, 88.2% of positive SEPT9 gene methylation patients turned to negative after colorectal cancer surgery, compared with this patients, the prognosis of patients whose SEPT9 methylation had not turned to negative had a poor prognosis.

Conclusion

SEPT9 gene methylation could be used as an important test indicator for the risk and prognosis of colorectal cancer.

图1 结直肠癌患者SEPT9基因甲基化检测
表1 783例筛查人群两组患者SEPT9、 CA125和CA199阳性率比较[例(%)]
表2 72例结直肠癌患者SEPT9基因甲基化病理因素比较[例(%)]
图2 783例患者SEPT9基因甲基化诊断结直肠癌的ROC曲线
表3 783例患者SEPT9、 CA125、 CA199的诊断效能
[1]
陈功,万德森.结直肠癌防治研究最新进展[J].广东医学,2016,37(22):3323-3328.
[2]
刘茉,王亚东,王贵齐,等.基于慢病管理的结直肠癌筛查模式初探[J].中华疾病控制杂志,2015,19(5):524-527.
[3]
李世拥,陈纲,杜峻峰,等.腹腔镜右半结肠癌根治术的临床疗效分析[J/CD].中华普外科手术学杂志:电子版,2015, 9(1):28-30.
[4]
蒋奕玫,赵任.肿瘤标志物在结直肠癌诊断中的作用[J].上海交通大学学报医学版,2015, 35(11):1734-1737.
[5]
Molnár B,Tóth K,Barták BK,et al.Plasma methylated septin 9: a colorectal cancer screening marker[J].Expert Rev Mol Diagn,2015,15(2):171-184.
[6]
Song L,Li Y.Chapter Four - SEPT9: A Specific Circulating Biomarker for Colorectal Cancer[J].Adv Clin Chem,2015,72(7):171-204.
[7]
Spiliotis ET,Kinoshita M,Nelson WJ.A mitotic septin scaffold required for Mammalian chromosome congression and segregation[J].Science,2005,307(5716):1781-1785.
[8]
Li Y,Song L,Gong Y,et al.Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future[J].Biomark Med,2014,8(5):755-769.
[9]
Payne SR.From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood[J].Epigenomics,2016,2(4):575-585.
[10]
Lofton-Day C,Model F,Devos T,et al.DNA methylation biomarkers for blood-based colorectal cancer screening[J].Clin Chem,2008,54(2):414-423.
[11]
Grützmann R,Molnar B,Pilarsky C,et al.Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay[J].Plos One,2008,3(11):e3759.
[12]
Wasserkort R,Kalmar A,Valcz G,et al.Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island[J].BMC Cancer,2013,13(1):398-398.
[13]
Yan S,Liu Z,Yu S,et al.Diagnostic Value of Methylated SEPT9 for Colorectal Cancer Screening: A Meta-Analysis[J].Med Sci Monit,2016,22(9):3409-3418.
[14]
Kang Q,Jin P,Yang L,et al.Significance of SEPT9 gene methylation detection of plasma circulation DNA in colorectal cancer screening[J].Zhonghua Yi Xue Za Zhi,2014,94(48):3839-3841.
[15]
贺娜,吴开春.血浆甲基化septin9基因与结直肠癌相关性的研究进展[J].中华消化杂志,2015,35(5):358-360.
[16]
Johnson DA,Barclay RL,Mergener K,et al.Plasma SEPT9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study[J].Plos One,2014,9(6):e98238.
[1] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[2] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3] 赵月, 田坤, 张宗明, 郭震天, 刘立民, 张翀, 刘卓. 降钙素原对老年急性重度胆囊炎发生的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 801-806.
[4] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[5] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[6] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[7] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[8] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[9] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[10] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[11] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[12] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[13] 季鹏程, 鄂一民, 陆晨, 喻春钊. 循环外泌体相关生物标志物在结直肠癌诊断中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 265-273.
[14] 李佳莹, 王旭丹, 梁雪, 张雷, 李佳英. 1990~2021年中国结直肠癌死亡趋势分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 274-279.
[15] 戈伟, 陈刚. 纳米炭导航行淋巴示踪在结直肠癌TNM分期中淋巴分期价值的临床研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 288-293.
阅读次数
全文


摘要